Novo Nordisk A/S (NVO)
| Market Cap | 575.53B |
| Revenue (ttm) | 35.35B |
| Net Income (ttm) | 12.92B |
| Shares Out | 4.54B |
| EPS (ttm) | 2.90 |
| PE Ratio | 43.83 |
| Forward PE | 39.53 |
| Dividend | $0.98 (0.77%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 3,037,416 |
| Open | 126.86 |
| Previous Close | 127.86 |
| Day's Range | 126.36 - 128.26 |
| 52-Week Range | 77.96 - 148.15 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 140.50 (+10.87%) |
| Earnings Date | Aug 7, 2024 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $140.5, which is an increase of 10.87% from the latest price.
News
Europe's Markets Are Cheap. 4 Stocks to Play.
Nevertheless, its member economies are poised for a rebound.
Novo Nordisk's Wegovy wins EU backing for reducing heart risks
Novo Nordisk's blockbuster Wegovy weight loss drug has received backing from the European Union's medical regulator to expand its use to include reducing the rise of serious heart events in overweight...
EU regulator backs use of Novo's Wegovy to lower heart risks
The European Medicines Agency has backed the use of Novo Nordisk's Wegovy to lower heart risks in overweight or obese adults, the company said on Thursday.
Viking's stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk
Experimental drug will move to late-stage trials, accelerating development timeline
UK Approves Novo Nordisk's Wegovy As First-Of-Its-Kind Treatment To Lower Heart Risks
Health regulators in the U.K. on Tuesday approved Novo Nordisk's weight loss injection semaglutide—the active ingredient in Ozempic and Wegovy—for lowering the risk of cardiovascular events in adults ...
Novo Nordisk's Wegovy approved by MHRA in the UK for cardiovascular prevention
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk's weight loss drug, Wegovy, for the prevention of serious cardiovascular events in overweight and obese ad...
Novo Nordisk's Wegovy weight loss drug wins UK approval for use as a heart treatment
The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy weight loss drug to reduce the risk of overweight and obese adults suffering from serious heart problems or strokes. It...
Novo Nordisk's Wegovy gets UK approval for lowering heart risks
Novo Nordisk's weight-loss drug Wegovy has secured the UK regulator's approval for its use to reduce the risk of overweight and obese adults suffering serious heart problems or strokes, the agency sai...
Wegovy-maker Novo Nordisk buys land in Denmark for potential new production plant
Novo Nordisk , the maker of weight-loss drug Wegovy, has bought a site in Denmark's third largest city Odense and begun preparatory excavation works for a potential new production plant, it said on Tu...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk, Eli Lilly have strong first-mover advantage: analyst
Emily Field, head of European pharmaceuticals research at Barclays, says it's too early to say what the competitive landscape will look like in five years for the weight loss drug market, as many tria...
Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
The famed Danish drug maker Novo Nordisk A/S NVO expressed disappointment on Wednesday following a recommendation by the Dutch Health Care Institute advising the Netherlands government against includi...
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its ex...
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss ...
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar...
Ozempic linked with lower dementia risk, nicotine use, British study finds
Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive problems, according to an observational study published by researchers at Oxford University.
Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates
American depositary receipts (ADRs) of Novo Nordisk (NVO) rose in intraday trading Friday after the release of an Oxford study that showed the Danish company's Ozempic diabetes drug was linked to lowe...
Study finds Novo Nordisk's Ozempic may reduce dementia
The study looked at semaglutide, the scientific name for Novo Nordisk's NVO, -2.07% NOVO.B, +0.52% Ozempic, with the intent of looking at whether it caused neurological problems. Instead, it found a 4...
US FDA declines to approve Novo Nordisk's weekly insulin
The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for...
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices
Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugma...
Weight Loss Drugs: Challenges with Affordability & Supply
Affordability and supply are key challenges for GLP-1 weight loss drugs but these issues are actively being addressed, notes Maurits Pot. He and Rahul Jasuja assess the market opportunity of this part...
Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin
Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior o...
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to fa...
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American dep...